Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27088820 | 0.81 | PAOX (0.36) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17555598 | 0.81 | TSHR (0.43) | KDM4EALDH1A1TSHRMAPK1MEN1 | |
| SCHEMBL25415513 | 0.81 | CYP2C9 (0.37) | KDM4EALDH1A1SMN1; SMN2TSHRMEN1 | |
| SCHEMBL19885951 | 0.80 | CA14 (0.37) | ALDH1A1TDP1 | |
| SCHEMBL7124808 | 0.80 | CYP2C9 (0.45) | KDM4EALDH1A1SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL21069229 | 0.80 | MEN1 (0.46) | KDM4EALDH1A1SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL21069994 | 0.80 | MEN1 (0.46) | KDM4EALDH1A1SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL21458802 | 0.80 | MEN1 (0.46) | KDM4EALDH1A1SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL12287335 | 0.79 | FPR3 (0.37) | KDM4EALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL22631509 | 0.78 | TSHR (0.45) | ALDH1A1SMN1; SMN2TSHRMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883926-B1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMA (US) | 2024-07-10 | — | — | EP | disclosed |
| US-11633492-B2 | Process for the synthesis of linker-drug vc-seco-DUBA | BYONDIS B.V. (NL) | 2023-04-25 | — | — | US | disclosed |
| EP-3883926-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | Regeneron Pharmaceuticals, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3713939-B1 | IMPROVED PROCESS FOR THE SYNTHESIS OF LINKER-DRUG VC-SECO | BYONDIS BV (NL) | 2021-07-21 | — | — | EP | disclosed |
| US-20200368362-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF LINKER-DRUG VC-SECO-DUBA | BYONDIS B.V. (NL) | 2020-11-26 | — | — | US | disclosed |
| EP-3713939-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF LINKER-DRUG VC-SECO | Byondis B.V. (NL) | 2020-09-30 | — | — | EP | disclosed |
| WO-2019101850-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF LINKER-DRUG VC-SECO-DUBA | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633492-B2 | Process for the synthesis of linker-drug vc-seco-DUBA | VCL, VCP, UBA2 | KDM4E 312/4885ALDH1A1 3334/4885SMN1; SMN2 2228/4885 |
| US-20200368362-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF LINKER-DRUG VC-SECO-DUBA | UBE3A, VCP, VCL | KDM4E 361/4885ALDH1A1 2631/4885SMN1; SMN2 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.